MarketsandMarkets

ImmunoBio Series USA Edition 2024

20th-21st June 2024

Boston, USA

Bridging Science, Innovation, and Health for a Better Tomorrow

MarketsandMarkets presents the Immunobio Series, an extraordinary set of conferences taking place on 20-21 June 2024 in Boston, USA.

MarketsandMarkets 5th Annual Biomarker and Companion Diagnostics Conference:

Immerse yourself in the realm of biomarkers at our flagship event, where industry leaders and experts converge to propel innovation in healthcare, diagnostics, and personalized medicine. This conference serves as a dynamic platform for collaboration, knowledge sharing, and exploration of cutting-edge biomarker research and applications. Esteemed keynote speakers will deliver groundbreaking insights into the latest developments and future prospects of biomarker research, making it a hub for fostering collaboration and driving innovation. Anticipated as the largest industry-led meeting, this conference unites over 200 senior decision-makers in the biomarker and CDx field, providing unparalleled insights. Attendees will gain actionable insights to identify biomarker and CDx development advancements across oncology and non-oncology indications, including Alzheimer’s, and Parkinson’s, revolutionizing personalized medicine pipelines. The summit will address challenges in analytical validation, explore regulatory landscapes, and leverage bioinformatics and AI for enhanced biomarker discovery. The 2024 summit promises an exclusive opportunity for knowledge sharing and networking among industry leaders, making a marked difference in patient outcomes.

MarketsandMarkets 7th Annual Next Gen Immuno-Oncology Conference:

Explore the forefront of cancer treatment at our flagship Immuno-Oncology Conference. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 40 speakers across the world from pharma, biopharma and biotech companies, the congress will discuss the latest updates and share insights in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy shaping the future of immuno-oncology.

Join us for this transformative event, where innovation meets collaboration, shaping the future of healthcare and biotechnology.

CO-LOCATED CONFERENCES

2nd Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference - East Coast Edition
7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference

WHAT TO EXPECT

  1. Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers.
  2. Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing treatments for individual patients, enhancing efficacy, and minimizing side effects.
  3. Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
  4. Clinical Applications Across Disorders: Delve into biomarker applications in cancer, immunology, neurodegenerative disorders, and cardiovascular conditions for targeted advancements.
  5. Bioinformatics and AI Analysis: Attend workshops and sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
  6. Biomarker-Based Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
  7. Regulatory Frameworks for CDx: Stay updated on current regulatory frameworks for CDx development, facilitating smoother approvals and applications.
  8. Expanding Biomarker Testing Access: Navigate reimbursement landscapes through cross-sector collaborations to widen access to biomarker testing.
  9. Innovative Strategies in CDx Development: Implement new CDx strategies to bring innovative therapies to the clinic, ensuring effective market access in line with global trends.

Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

  1. Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
  2. Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
  3. Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
  4. Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
  5. Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
  6. Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

CONFERENCE AGENDA

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

Keynote Presentation- Regulatory Framework for Biomarker Diagnostics: Insights and Strategies (Reserved Slot for Platinum Sponsor)

09:00 - 09:30

Modeling Strategies for Biomarker-driven Drug Discovery: PK/PD, QSP, and MIDD

09:30 - 10:00

Reserved Slot for Gold Sponsor

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Reserved Slot for Silver Sponsor

11:15 - 11:45

Advancing Digital Pathology in biomarker identification to revolutionize patient stratification

11:45 - 12:15

Facilitating Agile Global Drug Development with Precision Medicine-Driven Biomarker Deployment: Ensuring Harmonized Assays Across Varied Regional Regulations

Zheng Feng

Zheng Feng, Head, Molecular Biomarkers & Genomics, EMD Serono

12:15 - 12:45

Role of Biomarkers in Clinical Trials: Enhancing Patient Monitoring and Therapeutic Evaluation

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Functional biomarker assay development for cancer treatment (Solution Provider Presentation)

14:15 - 14:45

Assessing the Safety and Efficacy of ctDNA in Augmenting Immunotherapy Interventions

14:45 - 15:15

Dissection of the Tumor Microenvironment Using Spatial Transcriptomics and Deep Learning

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Predictive Modeling in Biomarker Research: Harnessing AI for Prognostic Signatures

16:30 - 17:00

Panel Discussion: Real world data for precision oncology based smart enrollment

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

Keynote Presentation (Reserved for Platinum Sponsor)

09:00 - 09:30

ADC drug and its applications

Siamak Tabrizi

Siamak Tabrizi, Senior Scientist, Immunitas Therapeutics

09:30 - 10:00

Reserved Slot for Gold Sponsor

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Reserved Slot for Silver Sponsor

11:15 - 11:45

SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers

Frank Borriello

Frank Borriello, Founder and CEO, Alloplex Biotherapeutics

11:45 - 12:15

Bispecific T-Cell engagers for cancer immunotherapy

12:15 - 12:45

Precision Immunology for targeted therapy

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Improving efficacy of CPI’s by selected combination therapy

14:15 - 14:45

Novel mRNA-based Immunotherapy Vaccines

14:45 - 15:15

Oncolytic viruses in the era of Checkpoint Blockade

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

16:30 - 17:00

Panel Discussions - Innovations in Immunotherapy: Unravelling the Trifecta - Precision Immunology, Cancer Microbiome, and CAR-T Cell Therapy for Personalized Cancer Treatment

17:00 - 17:30

Closing Remarks from the Chairperson

17:00 - 17:00

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

Keynote Presentation - Navigating CDx Partnerships: Strategies and Considerations for Pharma Companies (Reserved for Platinum Sponsor)

09:00 - 09:30

From Assay Development to Commercialization: CDx Strategy in Genetics Medicine

Melis McHenry

Melis McHenry, Associate Director, Precision Medicine CDx, Regeneron

09:30 - 10:00

Solution Provider Presentation-Reserved for Gold Sponsor

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Solution Provider Presentation (Reserved for Silver Sponsor)

11:15 - 11:45

Exploring International Regulatory and Commercial Considerations to shape the Future of Diagnostics

12:15 - 12:45

Global Commercialization and fast-tracked Market Access Strategies for Companion Diagnostics

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Leveraging IO markers for companion diagnostics development

14:15 - 14:45

Innovative Safety Biomarker Applications to Drug Development

14:45 - 15:15

Advancements in Imaging Biomarkers for Neurodegenerative Diagnosis and Monitoring

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Panel Discussion: Opportunities and Challenges in Biomarker Testing: Comparing Oncology and Non-Oncology Perspectives

16:30 - 17:00

Closing Remarks from the Chairperson

17:00 - 17:00

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

Keynote Presentation (Reserved for Platinum Sponsor)

09:00 - 09:30

Innovative Preclinical Models for Investigating Tumor-Immune Interactions

09:30 - 10:00

Solution Provider Presentation (Reserved for Gold Sponsor)

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Solution Provider Presentation (Reserved for Silver Sponsor)

11:15 - 11:45

Translational approach in developing right IO therapy

11:45 - 12:15

Development of new generation DNA vaccines

12:15 - 12:45

Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Future opportunities in clinical development of ICI’s

14:15 - 14:45

The Intersection of Immunology and Oncology: Advancing Targeted Therapy Paradigms

14:45 - 15:15

Challenges and Opportunities in Validating Preclinical Models for Immuno-Oncology Drug Development

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care

16:30 - 17:00

Closing Remarks from the Chairperson

17:00 - 17:00

SPEAKERS

Althea Lang

Althea Lang

Scientific Project Manager, Foundation for the National Institutes of Health

Neelam Bhardwaj

Neelam Bhardwaj

Product Development Lead, Novartis

Frank Borriello

Frank Borriello

Founder and CEO, Alloplex Biotherapeutics

Melis McHenry

Melis McHenry

Associate Director, Precision Medicine CDx, Regeneron

Cecilia Schott

Cecilia Schott

Vice President, Global Head Precision Diagnostics, Novartis AG

Nirmit Kumar

Nirmit Kumar

Senior Global Medical Affairs Leader, Diagnostic Oncology, AstraZeneca

Mario Flores

Mario Flores

Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio

Wenting Wang

Wenting Wang

Oncology Biomarker Statistics Team Lead, Sanofi

Amanda Acerbi

Amanda Acerbi

Precision Medicine Global Director, Janssen

Bhaskarjyoti Sarmah

Bhaskarjyoti Sarmah

Associate Scientific Director, Clinical Biomarkers, Moderna

Siamak Tabrizi

Siamak Tabrizi

Senior Scientist, Immunitas Therapeutics

Claudio Scuoppo

Claudio Scuoppo

Principal Scientist, Sapience Therapeutics

Rakesh Dixit

Rakesh Dixit

CEO, Bionavigen

Lindsay Darling

Lindsay Darling

Director, Companion Diagnostics Portfolio Management & Operations, Regeneron

Russell Weiner

Russell Weiner

Head Oncology and Cell Therapy Clinical Biomarker Sciences, Takeda

ENQUIRE NOW

SPONSORS

LOCATION

Venue

Boston, USA

PAST EVENT GALLERY